Breaking news—AbbVie to acquire Cerevel Therapeutics

US pharma major AbbVie has announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust pipeline. of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain.

AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash.

The transaction values Cerevel, a Pfizer spin-out, at a total equity value of approximately $8.7 billion.

Check the website later for major update.